340 patents currently held
19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
101
Ending by 2030
Dec 2026
Next term end
230
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2030 · High confidence
Also notable
Ends Feb 2039 · High confidence
Also notable
Ends Nov 2029 · High confidence
Methods for Prognosis of Future Acute Renal Injury and Acute Renal Failure
US 10,830,773
Cited by 29 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Sample Handling Systems, Mass Spectrometers and Related Methods
US 10,665,444
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2039.
Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
US 8,778,615
Cited by 40 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 21 to 28, 2026 · next Nov 21
- 4 fees due Dec 4 to 23, 2026 · next Dec 4
- 5 fees due Jan 2 to 30, 2027 · next Jan 2
- 6 fees due Feb 6 to 27, 2027 · next Feb 6
- 8 fees due Mar 3 to 29, 2027 · next Mar 3
- 12 fees due Apr 6 to 29, 2027 · next Apr 6
- 6 fees due May 3 to 19, 2027 · next May 3
- 5 fees due Jul 14 to 28, 2027 · next Jul 14
- 4 fees due Aug 6 to 20, 2027 · next Aug 6
- 7 fees due Sep 1 to 30, 2027 · next Sep 1
- 6 fees due Oct 7 to 26, 2027 · next Oct 7
- 1 fee due Nov 10, 2027The maintenance fee for Sliding Hinges and Related Methods and Devices Suitable for Apparatus for Automated Evaluation of Microorganism Growth in Test Samples (US 9,332,842) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
- 9 terms have ended since Aug 19, 2026
What they patent
The 5 largest of its 230 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,578,978 | Carrier for Holding Test Samples In force · High confidence | In force | High confidence | |
| US 8,623,293 | Sealer for test sample devices In force · High confidence | In force | High confidence | |
| US 8,168,387 | Oligonucleotides, Use Thereof, Detecting Method and Kit for Diagnosing the Presence of H5 and N1 Genes of the Influenza a Virus In force · High confidence | In force | High confidence | |
| US 8,008,009 | Method for Prongf Assay for in Vitro Diagnosis of Cancer in Particular Breast, Thyroid or Lung Cancer and Therapeutic Use of Prongf In force · High confidence | In force | High confidence | |
| US 8,512,636 | Compact, integrated system for processing test samples In force · High confidence | In force | High confidence | |
| US 8,741,655 | Transport system for test sample carrier In force · High confidence | In force | High confidence | |
| US 8,067,209 | Method of Screening for the Presence of a Genetic Defect Associated with Deep Venous Thrombosis held by Biomerieux B.V. In force · High confidence | In force | High confidence | |
| US D684,275 | Specimen Container In force · High confidence | In force | High confidence | |
| US 8,298,761 | Nucleic Acid Sequences That Can Be Used as Primers and Probes in the Amplification and Detection of HSV DNA and Method for the Amplification and Detection of HSV DNA Using a Transcription Based Amplification held by Biomerieux B.V. In force · High confidence | In force | High confidence | |
| US 7,601,300 | Compact, Integrated System for Processing Test Samples In force · High confidence | In force | High confidence |
Also on record, not counted in the 340: 19 patents in force now held by others · 170 patents ended · 39 applications pending · 142 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.